Literature DB >> 22892845

Adenovirus-mediated expression of mutated forkhead human transcription like-1 suppresses tumor growth in a mouse melanoma xenograft model.

Jorge G Gomez-Gutierrez1, Michael E Egger, Hongying Hao, Heshan Sam Zhou, Kelly M McMasters.   

Abstract

Melanoma is generally resistant to chemotherapy, which may be related to defects in death receptor signaling and to defects in induction of apoptosis. Forkhead family transcription factors induce the expression of death receptor ligands such as Fas ligand (Fas-L) resulting in apoptosis. We therefore investigated whether a triple mutant form of forkhead transcription factor FKHRL1 (FKHRL1/TM) can enhance Fas-L mediated-apoptosis in melanoma cells. Two melanoma cells A2058 or DM6 were tested for their sensitivity to agonistic anti-Fas antibody (CH-11); adenovirus expressing FKHRL1/TM (Ad-FKHRL1/TM) was assessed for its capability to induce activation of the caspase pathway; the role of Fas-L in the Ad-FKHRL1/TM mediated-cell death was also assessed in vitro. Ad-FKHRL1/TM antitumor activity in vivo was also evaluated in a mouse melanoma xenograft model. We found that DM6 melanoma cells were more resistant to Fas/Fas-L-mediated apoptosis induced by agonistic anti-Fas antibody than A2058 melanoma cells. Ectopic expression of FKHRL1/TM in melanoma cells upregulated Fas-L expression, decreased procaspase-8 levels, and significantly increased Fas/FasL-mediated cell death in both cells lines; this induced cell death was partially blocked by a Fas/Fas-L antagonist. Importantly, Ad-FKHRL1/TM treatment of subcutaneous melanoma xenografts in mice resulted in approximately 70% decrease in tumor size compared with controls. These data indicate that overexpression of FKHRL1/TM can induce the Fas-L pathway in melanoma cells. Ad-FKHRL1/TM therefore might represent a promising vector for melanoma treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892845      PMCID: PMC3469477          DOI: 10.4161/cbt.21349

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  23 in total

1.  Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

Authors:  A Brunet; A Bonni; M J Zigmond; M Z Lin; P Juo; L S Hu; M J Anderson; K C Arden; J Blenis; M E Greenberg
Journal:  Cell       Date:  1999-03-19       Impact factor: 41.582

2.  Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity.

Authors:  Sae Hee Ko; Tomio Ueno; Yasunori Yoshimoto; Jin Soo Yoo; Omar I Abdel-Wahab; Zeinab Abdel-Wahab; Edward Chu; Scott K Pruitt; Henry S Friedman; Mark W Dewhirst; Douglas S Tyler
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

Review 3.  Melanoma.

Authors:  Arlo J Miller; Martin C Mihm
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

4.  Visual screening for malignant melanoma: a cost-effectiveness analysis.

Authors:  Elena Losina; Rochelle P Walensky; Alan Geller; Frederick C Beddingfield; Lindsey L Wolf; Barbara A Gilchrest; Kenneth A Freedberg
Journal:  Arch Dermatol       Date:  2007-01

5.  Adenovirus-mediated gene transfer of FKHRL1 triple mutant efficiently induces apoptosis in melanoma cells.

Authors:  Jorge G Gomez-Gutierrez; Vinicius Souza; Hong Ying Hao; Roberto Montes de Oca-Luna; Yan Bin Dong; H Sam Zhou; Kelly M McMasters
Journal:  Cancer Biol Ther       Date:  2006-07-20       Impact factor: 4.742

6.  Ionizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosis.

Authors:  Jer-Yen Yang; Weiya Xia; Mickey C-T Hu
Journal:  Int J Oncol       Date:  2006-09       Impact factor: 5.650

7.  CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.

Authors:  Jürgen Eberle; Lothar F Fecker; Amir M Hossini; Thomas Wieder; Peter T Daniel; Constantin E Orfanos; Christoph C Geilen
Journal:  Oncogene       Date:  2003-12-11       Impact factor: 9.867

8.  Involvement of FKHRL1 in melanoma cell survival and death.

Authors:  C Hilmi; L Larribere; M Deckert; S Rocchi; S Giuliano; K Bille; J P Ortonne; R Ballotti; C Bertolotto
Journal:  Pigment Cell Melanoma Res       Date:  2008-04       Impact factor: 4.693

9.  Metaiodobenzylguanidine and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma.

Authors:  Robert J Canter; Rong Zhou; Susan B Kesmodel; Yawei Zhang; Daniel F Heitjan; Jerry D Glickson; Dennis B Leeper; Douglas L Fraker
Journal:  Ann Surg Oncol       Date:  2004-03       Impact factor: 5.344

Review 10.  FOXOs, cancer and regulation of apoptosis.

Authors:  Z Fu; D J Tindall
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

View more
  2 in total

1.  Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis.

Authors:  Rodolfo Garza-Morales; Kavitha Yaddanapudi; Rigoberto Perez-Hernandez; Eric Riedinger; Kelly M McMasters; Haval Shirwan; Esma Yolcu; Roberto Montes de Oca-Luna; Jorge G Gomez-Gutierrez
Journal:  Cancer Biol Ther       Date:  2018-01-22       Impact factor: 4.742

2.  Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide.

Authors:  Michael E Egger; Lacey R McNally; Jonathan Nitz; Kelly M McMasters; Jorge G Gomez-Gutierrez
Journal:  Hum Gene Ther Clin Dev       Date:  2014-09       Impact factor: 5.032

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.